A Promising New Treatment for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of estrogen and progesterone receptors and HER2. Unlike other breast cancer subtypes, TNBC does not respond to hormonal or HER2-targeted therapies, making treatment options limited. Researchers have been investigating novel therapeutic approaches, including immunotherapies, to improve outcomes in metastatic TNBC.

A recent phase 2 clinical trial published in JAMA Oncology demonstrated that the combination of the immunotherapy drug atezolizumab and the chemotherapy carboplatin significantly improved survival in patients with metastatic TNBC compared to carboplatin alone.

The Study and Its Implications

The trial enrolled 106 patients with metastatic TNBC who were randomized to receive intravenous carboplatin alone or carboplatin plus intravenous atezolizumab every 3 weeks. The combination treatment resulted in a near-doubling of progression-free survival from 2.2 months to 4.1 months and an improvement in overall survival from 8.6 months to 12.6 months compared to carboplatin alone.

Unlike previous clinical trials investigating atezolizumab in TNBC, this study showed a survival benefit regardless of PD-L1 expression status. Patients with high tumor mutation burden, tumor-infiltrating lymphocytes, obesity, and uncontrolled blood glucose levels appeared to derive the greatest benefit from the combination.

As Dr. Wael Harb, medical oncologist at MemorialCare Cancer Institute, explained, “The combination of immunotherapy (atezolizumab) and carboplatin improved the amount of time before disease progressed as well as patient’s overall survival when compared to carboplatin alone.”

The findings are clinically significant because they identify a new potential first-line treatment option for metastatic TNBC patients. If confirmed in phase 3 trials, the atezolizumab/carboplatin combination could become a new standard of care.

Why This Drug Combination May Be Effective

Typically, chemotherapy is the mainstay of treatment for TNBC given the lack of targets for therapy. However, as Dr. Brittney Zimmerman, medical oncologist at Northwell Health Cancer Institute, notes, recent data has shown improved outcomes when immunotherapy is combined with chemotherapy.

In this study, the researchers theorize that carboplatin and atezolizumab work synergistically through complementary mechanisms of action. Carboplatin causes DNA damage to cancer cells, while atezolizumab activates the immune system against cancer cells. The chemotherapy may also enhance the activity of the immunotherapy agent.

While atezolizumab combined with other chemotherapies failed to improve survival in past TNBC trials, carboplatin may be unique in its immunomodulating effects when paired with this immunotherapy.

Unanswered Questions and Next Steps

Further research is needed to validate and expand on these results before changing standard-of-care for patients with metastatic TNBC. The study was small, performed at a single institution, and lacked a placebo control arm.

Phase 3 randomized clinical trials will be important to reproduce the efficacy of atezolizumab and carboplatin in a larger patient population across multiple sites. Investigating this drug combination as initial therapy or in earlier lines of treatment is also of interest.

Identifying which patients are likely to respond through genomic profiling or other biomarkers will help select appropriate candidates for this regimen.

As Dr. Zimmerman stated, “Immunotherapy is an exciting class of medications in the field of medical oncology.” The atezolizumab and carboplatin regimen demonstrates promise as a new weapon against triple-negative breast cancer, one of the most difficult-to-treat forms of this disease.

The results offer renewed hope that through innovative therapeutic strategies, survival outcomes can continue to improve for TNBC patients. More definitive phase 3 trials are eagerly awaited to further evaluate this treatment approach.